MIRA INFORM REPORT
|
Report Date : |
28.11.2011 |
IDENTIFICATION DETAILS
|
Name : |
ALPHARMA ANIMAL HEALTH DIV |
|
|
|
|
Registered Office : |
400 Crossing Blvd, Ste 7, Bridgewater, NJ 08807-2863 |
|
|
|
|
Country : |
United States |
|
|
|
|
Date of Incorporation : |
Not Available |
|
|
|
|
Legal Form : |
Private Subsidiary Company |
|
|
|
|
Line of Business : |
manufacturing prepared feeds and feed ingredients
and adjuncts for animals and fowls, except dogs and cats |
|
|
|
|
No. of Employees
: |
115 Persons |
RATING & COMMENTS
|
MIRA’s Rating : |
A |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
Maximum Credit Limit : |
$50,000 (USD) |
|
Status : |
Good |
|
Payment
Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30th, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
Company name & address
Alpharma Animal Health Div
400 Crossing Blvd
Ste 7
Bridgewater, NJ 08807-2863
United States
Tel: 908-429-6000
Fax: 908-566-4129
Web: www.alpharmaah.com
Synthesis
Employees: 115
Company Type: Private Subsidiary
Corporate Family: 335
Companies
Ultimate Parent: Pfizer Inc.
Financials in: USD
(Millions)
Reporting Currency: US
Dollar
Annual Sales: 367.1
Total Assets: NA
Business Description
Establishments
primarily engaged in manufacturing prepared feeds and feed ingredients and
adjuncts for animals and fowls, except dogs and cats. Included in this industry
are poultry and livestock feed and feed ingredients, such as alfalfa meal, feed
supplements, and feed concentrates and feed premixes. Also included are
establishments primarily engaged in slaughtering animals for animal feed.
Industry
Industry Food Processing
ANZSIC 2006: 1192 - Prepared
Animal and Bird Feed Manufacturing
NACE 2002: 157 - Manufacture
of prepared animal feeds
NAICS 2002: 31111 - Animal
Food Manufacturing
UK SIC 2003: 157 - Manufacture
of prepared animal feeds
US SIC 1987: 2047 - Dog and Cat
Food
ABI Number: 891497687
1 - Profit & Loss Item Exchange Rate: USD 1 = USD 1
2 - Balance Sheet Item Exchange Rate: USD 1 = USD 1
Corporate Overview
Location
400 Crossing Blvd
Ste 7
Bridgewater, NJ, 08807-2863
Somerset County
United States
Tel: 908-429-6000
Fax: 908-566-4129
Web: www.alpharmaah.com
Sales USD(mil): 367.1
Assets USD(mil): NA
Employees: 115
Industry: Food Processing
Company Type: Private Subsidiary
Quoted Status: Not Quoted
Contents
· Industry Codes
· Business Description
· Financial Data
· Additional Information
Industry Codes
ANZSIC 2006 Codes:
1192 - Prepared Animal and Bird Feed Manufacturing
NACE 2002 Codes:
157 - Manufacture of prepared animal feeds
NAICS 2002 Codes:
31111 - Animal Food Manufacturing
US SIC 1987:
2047 - Dog and Cat Food
UK SIC 2003:
157 - Manufacture of prepared animal feeds
Business
Description
Establishments
primarily engaged in manufacturing prepared feeds and feed ingredients and
adjuncts for animals and fowls, except dogs and cats. Included in this industry
are poultry and livestock feed and feed ingredients, such as alfalfa meal, feed
supplements, and feed concentrates and feed premixes. Also included are
establishments primarily engaged in slaughtering animals for animal feed.
More Business Descriptions
Animal Food Manufacturing
|
|||||||||||||||||||||||||||||||||||
|
|
Credit Report as of 02/01/2011
|
Location |
|
|
400 Crossing Blvd Ste: 7 |
|
|
|
|
|
County: |
Somerset |
|
MSA: |
New York, NY |
|
|
|
|
Phone: |
908-429-6000 |
|
Fax: |
908-566-4129 |
|
URL: |
|
|
|
|
|
ABI©: |
891497687 |
|
|
|
|
Annual Sales: |
$367,056,000 (USD) |
|
Employees: |
115 |
|
|
|
|
Facility Size(ft2): |
40,000+ |
|
Facility Own/Lease: |
Lease |
|
|
|
|
Business Type: |
Private |
|
Location Type: |
Subsidiary |
|
Corp. Affiliation: |
|
|
|
|
|
Recommended
Credit Limit * |
|
|
$50,000 (USD) |
|
|
|
|
|
Primary Line Of Business: |
|
|
SIC: |
2048-01 - Animal Health Products-Manufacturers |
|
NAICS: |
311119 - Other Animal Food Mfg |
|
Secondary Lines Of
Business: |
|
|
SICs: |
8742-13 - Marketing Programs & Services |
|
NAICS: |
541613 - Marketing Consulting Svcs |
Table of Contents
Profile Links
Similar Businesses in the Area
Closest Neighbors
External Links
http://alpharmaah.com
Parent OneSource Profile
Merck Animal
Health
29160 Intervet Ln
Millsboro, DE 19966-4217
Yellow Roof Pet
Care
1019 Main St
Asbury Park, NJ 07712-5922
Brandt's Feed Mill
630 N 9th St
Lebanon, PA 17046-3499
Tommy Lynn's
Grooming Boutique
631 Aiken Ave
Perryville, MD 21903-2733
Horse Eczema &
Sweet Itch
9 Windsor Pl
Essex Fells, NJ 07021-1710
Celltei
128 Waterbury St
Brooklyn, NY 11206-1617
DBC Agricultural
Products
313 W Liberty St Ste: 237
Lancaster, PA 17603-2766
Howell Animal
Hospital
2354 US Highway 9
Howell, NJ 07731-4017
J-B Pet Supply
Outlet Store
289 Wagaraw Rd
Hawthorne, NJ 07506-1411
* Similar Businesses are
defined as the closest businesses sharing the same six-digit primary SIC code (
2048-01 - Animal Health Products-Manufacturers) regardless of size.
Closest Neighbors
Apparel
Contractors
1 Executive Dr Ste: 210
Fort Lee, NJ 07024-3381
East Hill Lending
1 Executive Dr Ste: 605
Fort Lee, NJ 07024-3381
Dpc Data Inc
103 Eisenhower Pkwy Ste: 300
Roseland, NJ 07068-1029
Compass Maritime
Services LLC
1 Executive Dr Ste: 180
Fort Lee, NJ 07024-3326
Art Distribution
Inc
1 Marine Plz Ste: 305
North Bergen, NJ 07047-6234
American Risk
Management Inc Armrisk
1 Executive Dr
Fort Lee, NJ 07024-3309
|
Corporate
Family |
Corporate
Structure News: |
|
|
|
|
Alpharma Animal
Health Div |
|
|
|
|
|
|
|
|
Company Name |
Company Type |
Location |
Country |
Industry |
Sales |
Employees |
|
|
Parent |
NEW YORK, NY |
United States |
Biotechnology and Drugs |
67,809.0 |
110,600 |
|
|
|
Acquisition of Excaliard Pharmaceuticals
Inc proposed/announced.See corporate
structure news on
Pfizer Inc. for details |
|||||||
|
Subsidiary |
Beijing |
China |
Biotechnology and Drugs |
1.0 |
10,000 |
|
|
|
Subsidiary |
Collegeville, PA |
United States |
Biotechnology and Drugs |
18,622.0 |
4,500 |
|
|
|
Subsidiary |
Groton, CT |
United States |
Biotechnology and Drugs |
|
3,800 |
|
|
|
Subsidiary |
São Paulo, SP |
Brazil |
Biotechnology and Drugs |
1,931.9 |
3,490 |
|
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
295.3 |
3,177 |
|
|
|
Subsidiary |
Roma, Roma (Rome) |
Italy |
Biotechnology and Drugs |
1,728.6 |
2,992 |
|
|
|
Subsidiary |
Bristol, TN |
United States |
Biotechnology and Drugs |
2,521.8 |
2,649 |
|
|
|
Recently acquired (previously owned by King
Pharmaceuticals, Inc.).See corporate
structure news on
Pfizer Inc. for details |
|||||||
|
Subsidiary |
Latina, LT |
Italy |
Biotechnology and Drugs |
1,728.6 |
2,500 |
|
|
|
Subsidiary |
Aprilia, LT |
Italy |
Biotechnology and Drugs |
1,150.0 |
2,000 |
|
|
|
Subsidiary |
Berlin |
Germany |
Biotechnology and Drugs |
449.1 |
1,950 |
|
|
|
Subsidiary |
Berlin, Berlin |
Germany |
Miscellaneous Capital Goods |
1,365.5 |
1,950 |
|
|
|
Subsidiary |
Karlsruhe |
Germany |
Biotechnology and Drugs |
1.0 |
1,100 |
|
|
|
Subsidiary |
Illertissen |
Germany |
Biotechnology and Drugs |
104.3 |
560 |
|
|
|
Subsidiary |
Illertissen, Bayern |
Germany |
Biotechnology and Drugs |
102.6 |
500 |
|
|
|
Subsidiary |
Karlsruhe |
Germany |
Miscellaneous Financial Services |
1.0 |
15 |
|
|
|
Subsidiary |
Freiburg |
Germany |
Biotechnology and Drugs |
450.0 |
|
|
|
|
Subsidiary |
Berlin, Berlin |
Germany |
Real Estate Operations |
|
|
|
|
|
Branch |
Andover, MA |
United States |
Biotechnology and Drugs |
1,428.0 |
1,500 |
|
|
|
Subsidiary |
Vega Baja |
Puerto Rico |
Biotechnology and Drugs |
875.0 |
1,500 |
|
|
|
Subsidiary |
Istanbul |
Turkey |
Biotechnology and Drugs |
|
1,426 |
|
|
|
Subsidiary |
São Paulo |
Brazil |
Biotechnology and Drugs |
|
1,420 |
|
|
|
Subsidiary |
Alcobendas, Madrid |
Spain |
Biotechnology and Drugs |
1,481.6 |
1,360 |
|
|
|
Branch |
Barcelona |
Spain |
Biotechnology and Drugs |
|
725 |
|
|
|
Subsidiary |
Alcobendas |
Spain |
Food Processing |
125.0 |
|
|
|
|
Subsidiary |
El Prat de Llobregat |
Spain |
Food Processing |
75.0 |
|
|
|
|
Branch |
Saint-Laurent, QC |
Canada |
Biotechnology and Drugs |
1,383.4 |
1,300 |
|
|
|
Subsidiary |
Puurs |
Belgium |
Biotechnology and Drugs |
331.0 |
1,291 |
|
|
|
Subsidiary |
Puurs |
Belgium |
Commercial Banks |
0.0 |
|
|
|
|
Subsidiary |
West Ryde, NSW |
Australia |
Biotechnology and Drugs |
1,021.0 |
1,150 |
|
|
|
Subsidiary |
Bentley, WA |
Australia |
Biotechnology and Drugs |
|
|
|
|
|
Branch |
Brooklyn, NY |
United States |
Biotechnology and Drugs |
1,047.2 |
1,100 |
|
|
|
Subsidiary |
Madison, NJ |
United States |
Personal and Household Products |
1,090.0 |
1,000 |
|
|
|
Subsidiary |
Madison, NJ |
United States |
Biotechnology and Drugs |
2,500.0 |
3,100 |
|
|
|
Subsidiary |
Naucalpan de Juárez, Estado de México |
Mexico |
Biotechnology and Drugs |
5,027.8 |
1,000 |
|
|
|
Subsidiary |
Naucalpan |
Mexico |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
São Paulo, SP |
Brazil |
Biotechnology and Drugs |
398.9 |
800 |
|
|
|
Subsidiary |
Sydney, NSW |
Australia |
Biotechnology and Drugs |
|
700 |
|
|
|
Subsidiary |
San Sebastian De Los Reyes, Madrid |
Spain |
Biotechnology and Drugs |
1,146.3 |
671 |
|
|
|
Subsidiary |
La Vall De Bianya, Girona |
Spain |
Biotechnology and Drugs |
105.1 |
190 |
|
|
|
Subsidiary |
Mumbai |
India |
Biotechnology and Drugs |
144.8 |
512 |
|
|
|
Subsidiary |
Karachi |
Pakistan |
Biotechnology and Drugs |
27.2 |
304 |
|
|
|
Subsidiary |
Campinas, Sao Paulo |
Brazil |
Crops |
|
300 |
|
|
|
Subsidiary |
Solna |
Sweden |
Personal and Household Products |
357.7 |
240 |
|
|
|
Branch |
Glostrup |
Denmark |
Medical Equipment and Supplies |
|
35 |
|
|
|
Subsidiary |
Capital Federal, Buenos Aires |
Argentina |
Biotechnology and Drugs |
71.0 |
210 |
|
|
|
Subsidiary |
Caracas |
Venezuela |
Biotechnology and Drugs |
60.0 |
200 |
|
|
|
Subsidiary |
Bogota, Cundinamarca |
Colombia |
Miscellaneous Capital Goods |
60.0 |
200 |
|
|
|
Subsidiary |
Kuningan, Jakarta Selatan |
Indonesia |
Miscellaneous Capital Goods |
48.0 |
160 |
|
|
|
Subsidiary |
Algés |
Portugal |
Personal and Household Products |
89.2 |
130 |
|
|
|
Subsidiary |
Johannesburg |
South Africa |
Miscellaneous Capital Goods |
36.0 |
100 |
|
|
|
Subsidiary |
Buenos Aires, Buenos Aires |
Argentina |
Crops |
34.0 |
100 |
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
9.7 |
100 |
|
|
|
Division |
Yannawa, Sathorn, Bangkok |
Thailand |
Miscellaneous Capital Goods |
|
100 |
|
|
|
Subsidiary |
Aberdeen |
United Kingdom |
Biotechnology and Drugs |
0.0 |
25 |
|
|
|
Subsidiary |
Alton |
United Kingdom |
Printing and Publishing |
|
1 |
|
|
|
Subsidiary |
Alton |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Alton |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Puteaux |
France |
Biotechnology and Drugs |
350.0 |
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Commercial Banks |
|
|
|
|
|
Subsidiary |
Maidenhead |
United Kingdom |
Business Services |
57.5 |
174 |
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Personal and Household Products |
53.3 |
36 |
|
|
|
Subsidiary |
Southampton |
United Kingdom |
Nonclassifiable Industries |
38.4 |
36 |
|
|
|
Subsidiary |
London |
United Kingdom |
Commercial Banks |
|
|
|
|
|
Subsidiary |
London |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Commercial Banks |
|
|
|
|
|
Subsidiary |
Maidenhead |
United Kingdom |
Biotechnology and Drugs |
1,786.6 |
617 |
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Lima |
Peru |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Shanghai, Shanghai |
China |
Business Services |
|
|
|
|
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Shanghai, Shanghai |
China |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Baulkham HIlls, NSW |
Australia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Petaling Jaya, Selangor |
Malaysia |
Food Processing |
|
|
|
|
|
Subsidiary |
Barceloneta |
Puerto Rico |
Biotechnology and Drugs |
450.0 |
1,000 |
|
|
|
Subsidiary |
Guaynabo |
Puerto Rico |
Biotechnology and Drugs |
75.0 |
900 |
|
|
|
Subsidiary |
Jakarta Pusat |
Indonesia |
Miscellaneous Capital Goods |
30.0 |
890 |
|
|
|
Subsidiary |
Giza |
Egypt |
Miscellaneous Capital Goods |
60.0 |
817 |
|
|
|
Branch |
Rouses Point, NY |
United States |
Biotechnology and Drugs |
761.6 |
800 |
|
|
|
Subsidiary |
Makati City |
Philippines |
Biotechnology and Drugs |
379.3 |
800 |
|
|
|
Subsidiary |
Cairo |
Egypt |
Biotechnology and Drugs |
|
800 |
|
|
|
Subsidiary |
Caracas DF |
Venezuela |
Biotechnology and Drugs |
0.2 |
780 |
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
346.0 |
763 |
|
|
|
Subsidiary |
Sandton |
South Africa |
Biotechnology and Drugs |
150.0 |
750 |
|
|
|
Subsidiary |
North Point, Hong Kong Island |
Hong Kong |
Biotechnology and Drugs |
60.0 |
750 |
|
|
|
Subsidiary |
Makati City |
Philippines |
Biotechnology and Drugs |
114.7 |
720 |
|
|
|
Subsidiary |
Bogotá DC |
Colombia |
Personal and Household Products |
248.6 |
650 |
|
|
|
Subsidiary |
Kirkland, QC |
Canada |
Biotechnology and Drugs |
|
600 |
|
|
|
Branch |
Thornhill, ON |
Canada |
Personal and Household Products |
387.2 |
220 |
|
|
|
Branch |
Brandon, MB |
Canada |
Personal and Household Products |
248.9 |
135 |
|
|
|
Subsidiary |
Co. Limerick |
Ireland |
Food Processing |
380.3 |
581 |
|
|
|
Subsidiary |
México |
Mexico |
Biotechnology and Drugs |
350.0 |
550 |
|
|
|
Subsidiary |
México DF |
Mexico |
Biotechnology and Drugs |
672.2 |
1,750 |
|
|
|
Subsidiary |
Neo Psychiko |
Greece |
Biotechnology and Drugs |
572.1 |
530 |
|
|
|
Branch |
Memphis, TN |
United States |
Biotechnology and Drugs |
476.0 |
500 |
|
|
|
Subsidiary |
Silom, Bangrak, Bangkok |
Thailand |
Biotechnology and Drugs |
212.0 |
500 |
|
|
|
Subsidiary |
Bruxelles |
Belgium |
Biotechnology and Drugs |
631.2 |
456 |
|
|
|
Subsidiary |
Puurs |
Belgium |
Biotechnology and Drugs |
|
1,600 |
|
|
|
Subsidiary |
Bornem |
Belgium |
Chemical Manufacturing |
215.9 |
470 |
|
|
|
Subsidiary |
Zaventem |
Belgium |
Trucking |
|
360 |
|
|
|
Subsidiary |
Frankfurt am Main |
Germany |
Biotechnology and Drugs |
1.0 |
400 |
|
|
|
Subsidiary |
København S |
Denmark |
Biotechnology and Drugs |
135.8 |
372 |
|
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
150.0 |
350 |
|
|
|
Subsidiary |
Esentepe, Istanbul |
Turkey |
Biotechnology and Drugs |
119.0 |
350 |
|
|
|
Subsidiary |
Warsaw |
Poland |
Biotechnology and Drugs |
60.0 |
350 |
|
|
|
Branch |
Memphis, TN |
United States |
Biotechnology and Drugs |
285.6 |
300 |
|
|
|
Subsidiary |
Selangor Darul Ehsan, Selangor |
Malaysia |
Biotechnology and Drugs |
100.0 |
300 |
|
|
|
Subsidiary |
Strängnäs, Södermanland |
Sweden |
Biotechnology and Drugs |
763.1 |
290 |
|
|
|
Subsidiary |
Sollentuna |
Sweden |
Personal and Household Products |
289.4 |
252 |
|
|
|
Subsidiary |
Budapest |
Hungary |
Personal and Household Products |
|
290 |
|
|
|
Subsidiary |
Ciudad De Buenos Aires, Ciudad De Buenos Aires |
Argentina |
Biotechnology and Drugs |
86.9 |
280 |
|
|
|
Subsidiary |
Co Dublin |
Ireland |
Biotechnology and Drugs |
204.8 |
270 |
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
3,047.8 |
250 |
|
|
|
Subsidiary |
Cerrillos, Santiago |
Chile |
Miscellaneous Capital Goods |
30.0 |
250 |
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
96.0 |
225 |
|
|
|
Subsidiary |
Lima |
Peru |
Personal and Household Products |
30.0 |
200 |
|
|
|
Subsidiary |
Danshuei, Taipei |
Taiwan |
Personal and Household Products |
1.0 |
200 |
|
|
|
Subsidiary |
Auckland |
New Zealand |
Biotechnology and Drugs |
133.7 |
180 |
|
|
|
Subsidiary |
Louvain-La-Neuve |
Belgium |
Biotechnology and Drugs |
185.7 |
179 |
|
|
|
Subsidiary |
Wien |
Austria |
Personal and Household Products |
222.0 |
170 |
|
|
|
Subsidiary |
Ballerup |
Denmark |
Personal and Household Products |
129.3 |
162 |
|
|
|
Subsidiary |
Athens |
Greece |
Biotechnology and Drugs |
|
160 |
|
|
|
Subsidiary |
Singapore |
Singapore |
Biotechnology and Drugs |
|
150 |
|
|
|
Subsidiary |
Montevideo |
Uruguay |
Biotechnology and Drugs |
|
150 |
|
|
|
Subsidiary |
San Diego, CA |
United States |
Biotechnology and Drugs |
|
148 |
|
|
|
Subsidiary |
Nossegem |
Belgium |
Personal and Household Products |
34.3 |
140 |
|
|
|
Branch |
St Petersburg, FL |
United States |
Personal and Household Products |
114.2 |
120 |
|
|
|
Branch |
Middleton, WI |
United States |
Personal and Household Products |
153.2 |
110 |
|
|
|
Subsidiary |
Mississauga, ON |
Canada |
Biotechnology and Drugs |
182.1 |
100 |
|
|
|
Subsidiary |
Lysaker |
Norway |
Personal and Household Products |
141.8 |
91 |
|
|
|
Subsidiary |
Berlin |
Germany |
Personal and Household Products |
102.1 |
90 |
|
|
|
Subsidiary |
Santiago |
Chile |
Healthcare Facilities |
32.0 |
90 |
|
|
|
Subsidiary |
Zug |
Switzerland |
Biotechnology and Drugs |
|
80 |
|
|
|
Branch |
Westlake, TX |
United States |
Biotechnology and Drugs |
75.2 |
79 |
|
|
|
Subsidiary |
Zürich |
Switzerland |
Biotechnology and Drugs |
342.7 |
75 |
|
|
|
Subsidiary |
S San Francisco, CA |
United States |
Healthcare Facilities |
|
75 |
|
|
|
Subsidiary |
Zagreb |
Croatia |
Miscellaneous Capital Goods |
37.0 |
72 |
|
|
|
Branch |
Cary, NC |
United States |
Biotechnology and Drugs |
66.6 |
70 |
|
|
|
Branch |
Reston, VA |
United States |
Biotechnology and Drugs |
66.6 |
70 |
|
|
|
Branch |
Franklin, OH |
United States |
Biotechnology and Drugs |
66.6 |
70 |
|
|
|
Division |
Kalamazoo, MI |
United States |
Biotechnology and Drugs |
|
67 |
|
|
|
Subsidiary |
Wien, Wien |
Austria |
Biotechnology and Drugs |
89.6 |
55 |
|
|
|
Branch |
New Haven, CT |
United States |
Biotechnology and Drugs |
47.6 |
50 |
|
|
|
Subsidiary |
Dublin |
Ireland |
Biotechnology and Drugs |
|
50 |
|
|
|
Subsidiary |
Newbridge |
Ireland |
Biotechnology and Drugs |
|
1,400 |
|
|
|
Subsidiary |
Budapest |
Hungary |
Biotechnology and Drugs |
|
50 |
|
|
|
Subsidiary |
New York, NY |
United States |
Business Services |
|
48 |
|
|
|
Subsidiary |
King Of Prussia, PA |
United States |
Biotechnology and Drugs |
|
43 |
|
|
|
Subsidiary |
Columbia, MD |
United States |
Medical Equipment and Supplies |
|
43 |
|
|
|
Branch |
St Louis, MO |
United States |
Medical Equipment and Supplies |
6.4 |
20 |
|
|
|
Branch |
White Hall, IL |
United States |
Biotechnology and Drugs |
39.0 |
41 |
|
|
|
Branch |
Ewing, NJ |
United States |
Airlines |
4.0 |
40 |
|
|
|
Subsidiary |
Durham, NC |
United States |
Biotechnology and Drugs |
|
38 |
|
|
|
Recently acquired (previously owned by
Icagen, Inc.).See corporate
structure news on
Pfizer Inc. for details |
|||||||
|
Subsidiary |
Seoul, Seoul |
Korea, Republic of |
Biotechnology and Drugs |
|
37 |
|
|
|
Branch |
Sparks, NV |
United States |
Biotechnology and Drugs |
33.3 |
35 |
|
|
|
Subsidiary |
Columbia, MD |
United States |
Biotechnology and Drugs |
3.4 |
35 |
|
|
|
Subsidiary |
Houston, TX |
United States |
Biotechnology and Drugs |
|
30 |
|
|
|
Subsidiary |
Cambridge, MA |
United States |
Biotechnology and Drugs |
|
30 |
|
|
|
Branch |
Reno, NV |
United States |
Biotechnology and Drugs |
27.6 |
29 |
|
|
|
Branch |
Washington, DC |
United States |
Biotechnology and Drugs |
26.7 |
28 |
|
|
|
Subsidiary |
Oslo |
Norway |
Biotechnology and Drugs |
|
27 |
|
|
|
Subsidiary |
Quito |
Ecuador |
Biotechnology and Drugs |
|
25 |
|
|
|
Subsidiary |
Durham, NC |
United States |
Biotechnology and Drugs |
|
25 |
|
|
|
Subsidiary |
Auckland |
New Zealand |
Biotechnology and Drugs |
|
22 |
|
|
|
Subsidiary |
Peapack, NJ |
United States |
Biotechnology and Drugs |
10.4 |
20 |
|
|
|
Subsidiary |
Colmar |
France |
Chemical Manufacturing |
133.1 |
357 |
|
|
|
Branch |
Lees Summit, MO |
United States |
Biotechnology and Drugs |
223.7 |
235 |
|
|
|
Subsidiary |
Ayutthaya |
Thailand |
Biotechnology and Drugs |
1.0 |
200 |
|
|
|
Subsidiary |
Chandigarh, Chandigarh |
India |
|
|
150 |
|
|
|
Subsidiary |
Jiangsu |
China |
Miscellaneous Capital Goods |
18.0 |
|
|
|
|
Subsidiary |
San Diego, CA |
United States |
Biotechnology and Drugs |
|
18 |
|
|
|
Subsidiary |
Paris |
France |
Commercial Banks |
176.4 |
14 |
|
|
|
Subsidiary |
Poce Sur Cisse |
France |
Biotechnology and Drugs |
169.0 |
671 |
|
|
|
Subsidiary |
Paris |
France |
Computer Services |
124.2 |
|
|
|
|
Subsidiary |
Ratingen, Nordrhein-Westfalen |
Germany |
Personal and Household Products |
|
12 |
|
|
|
Subsidiary |
Dublin |
Ireland |
Commercial Banks |
87.0 |
6 |
|
|
|
Subsidiary |
Markham, ON |
Canada |
Personal and Household Products |
9.6 |
6 |
|
|
|
Subsidiary |
Brooklyn, NY |
United States |
Biotechnology and Drugs |
3.8 |
4 |
|
|
|
Subsidiary |
Tokyo |
Japan |
Biotechnology and Drugs |
4,598.2 |
|
|
|
|
Subsidiary |
Sagamihara |
Japan |
Biotechnology and Drugs |
1.0 |
|
|
|
|
Subsidiary |
Tokyo |
Japan |
Chemical Manufacturing |
702.4 |
|
|
|
|
Subsidiary |
Co Cork |
Ireland |
Biotechnology and Drugs |
570.4 |
|
|
|
|
Subsidiary |
Münster |
Germany |
Biotechnology and Drugs |
250.0 |
|
|
|
|
Subsidiary |
Karachi |
Pakistan |
Biotechnology and Drugs |
250.0 |
|
|
|
|
Subsidiary |
Solna |
Sweden |
Biotechnology and Drugs |
175.0 |
|
|
|
|
Subsidiary |
Piscataway, NJ |
United States |
Biotechnology and Drugs |
167.7 |
|
|
|
|
Subsidiary |
Manati |
Puerto Rico |
Scientific and Technical Instruments |
75.0 |
|
|
|
|
Subsidiary |
Buenos Aires |
Argentina |
Healthcare Facilities |
75.0 |
|
|
|
|
Subsidiary |
Karachi |
Pakistan |
Biotechnology and Drugs |
75.0 |
|
|
|
|
Subsidiary |
San Sebastián de los Rey |
Spain |
Biotechnology and Drugs |
75.0 |
|
|
|
|
Subsidiary |
Manati |
Puerto Rico |
Chemical Manufacturing |
75.0 |
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Commercial Banks |
61.9 |
|
|
|
|
Subsidiary |
Milton Keynes |
United Kingdom |
Commercial Banks |
|
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Corby |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Commercial Banks |
|
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Commercial Banks |
|
|
|
|
|
Subsidiary |
Seoul |
Korea, Republic of |
Biotechnology and Drugs |
13.3 |
|
|
|
|
Subsidiary |
Island East |
Hong Kong |
Biotechnology and Drugs |
1.0 |
|
|
|
|
Subsidiary |
|
Ireland |
Commercial Banks |
0.8 |
|
|
|
|
Subsidiary |
Capelle Aan Den Ijssel, Zuid-Holland |
Netherlands |
Miscellaneous Financial Services |
0.4 |
|
|
|
|
Subsidiary |
Puurs |
Belgium |
Personal and Household Products |
0.0 |
|
|
|
|
Subsidiary |
Suzhou, Jiang Su |
China |
Biotechnology and Drugs |
0.0 |
|
|
|
|
Subsidiary |
Shanghai |
China |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Puebla, Puebla |
Mexico |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Algiers |
Algeria |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Taipei |
Taiwan |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Heredia |
Costa Rica |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Capelle Aan Den Ijssel, Zuid-Holland |
Netherlands |
Miscellaneous Financial Services |
|
|
|
|
|
Subsidiary |
Cibinong, Jawa Barat |
Indonesia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Bratislava |
Slovakia |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
New York, NY |
United States |
Fish and Livestock |
|
|
|
|
|
Branch |
Kalamazoo, MI |
United States |
Biotechnology and Drugs |
1,320.0 |
6,000 |
|
|
|
Subsidiary |
Bridgewater, NJ |
United States |
Biotechnology and Drugs |
722.4 |
2,000 |
|
|
|
Subsidiary |
Oslo |
Norway |
Personal and Household Products |
40.7 |
163 |
|
|
|
Branch |
Lincoln, NE |
United States |
Biotechnology and Drugs |
856.8 |
900 |
|
|
|
Branch |
Fort Dodge, IA |
United States |
Biotechnology and Drugs |
466.2 |
900 |
|
|
|
Branch |
Charles City, IA |
United States |
Biotechnology and Drugs |
187.5 |
362 |
|
|
|
Subsidiary |
Overland Park, KS |
United States |
Fish and Livestock |
103.6 |
200 |
|
|
|
Subsidiary |
Bridgewater, NJ |
United States |
Food Processing |
367.1 |
115 |
|
|
|
Subsidiary |
Sligo |
Ireland |
Biotechnology and Drugs |
|
100 |
|
|
|
Subsidiary |
Guelph, ON |
Canada |
Biotechnology and Drugs |
19.8 |
45 |
|
|
|
Subsidiary |
Durham, NC |
United States |
Fish and Livestock |
52.6 |
120 |
|
|
|
Subsidiary |
Würselen |
Germany |
Business Services |
26.1 |
40 |
|
|
|
Subsidiary |
Kansas City, MO |
United States |
Fish and Livestock |
19.2 |
35 |
|
|
|
Recently acquired (previously owned by
Synbiotics Corporation).See corporate
structure news on
Pfizer Inc. for details |
|||||||
|
Subsidiary |
Lyon |
France |
Biotechnology and Drugs |
7.6 |
74 |
|
|
|
Subsidiary |
Saanichton, BC |
Canada |
Fish and Livestock |
|
12 |
|
|
|
Subsidiary |
JG Hoofddorp |
Netherlands |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Royston |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Joint Venture |
Phra Nakhon Si Ayutthaya |
Thailand |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Oxford |
United Kingdom |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Sandwich |
United Kingdom |
Nonclassifiable Industries |
|
|
|
|
|
Subsidiary |
Dubai |
United Arab Emirates |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Dublin |
Ireland |
Commercial Banks |
|
|
|
|
|
Joint Venture |
Caringbah, NSW |
Australia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Praha |
Czech Republic |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Tallinn |
Estonia |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
London |
United Kingdom |
Biotechnology and Drugs |
|
|
|
|
|
Branch |
Vilnius |
Lithuania |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Ljubljana |
Slovenia |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Ho Chi Minh City |
Viet Nam |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
North Point, Hong Kong Island |
Hong Kong |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
México DF, Federal District |
Mexico |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Sofia |
Bulgaria |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Shanghai, Shanghai |
China |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Riga |
Latvia |
Miscellaneous Capital Goods |
|
|
|
|
|
Subsidiary |
Vega Baja |
Puerto Rico |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Bucharest |
Romania |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Dubai Media |
United Arab Emirates |
Biotechnology and Drugs |
|
|
|
|
|
Subsidiary |
Casablanca |
Morocco |
Biotechnology and Drugs |
|
|
|
|
|
Pfizer Holdings Ireland |
Subsidiary |
|
|
|
|
|
|
|
Subsidiary |
Paris |
France |
Biotechnology and Drugs |
2,171.7 |
1,499 |
|
|
|
Subsidiary |
Louvain-La-Neuve |
Belgium |
Biotechnology and Drugs |
144.7 |
259 |
|
|
|
Subsidiary |
Porto Salvo |
Portugal |
Personal and Household Products |
343.2 |
402 |
|
|
|
Subsidiary |
Capelle aan den IJssel |
Netherlands |
Personal and Household Products |
329.6 |
350 |
|
|
|
Subsidiary |
Capelle Aan Den Ijssel, Zuid-Holland |
Netherlands |
Personal and Household Products |
35.6 |
25 |
|
|
|
Subsidiary |
Capelle Aan Den Ijssel, Zuid-Holland |
Netherlands |
Personal and Household Products |
|
|
|
|
|
Subsidiary |
Helsinki |
Finland |
Personal and Household Products |
169.6 |
159 |
|
|
Standard
& Poor’s
|
United
States of America Long-Term Rating Lowered To 'AA+' Due To Political Risks,
Rising Debt Burden; Outlook Negative |
|
Publication
date: 05-Aug-2011 20:13:14 EST |
·
We have lowered our long-term
sovereign credit rating on the United States of America to 'AA+' from 'AAA' and
affirmed the 'A-1+' short-term rating.
·
We have also removed both the short- and long-term ratings
from CreditWatch negative.
·
The downgrade reflects our opinion that the fiscal
consolidation plan that Congress and the Administration recently agreed to
falls short of what, in our view, would be necessary to stabilize the
government's medium-term debt dynamics.
·
More broadly, the downgrade reflects our view that the
effectiveness, stability, and predictability of American policymaking and
political institutions have weakened at a time of ongoing fiscal and economic
challenges to a degree more than we envisioned when we assigned a negative
outlook to the rating on April 18, 2011.
·
Since then, we have changed our view of the difficulties in
bridging the gulf between the political parties over fiscal policy, which makes
us pessimistic about the capacity of Congress and the Administration to be able
to leverage their agreement this week into a broader fiscal consolidation plan
that stabilizes the government's debt dynamics any time soon.
·
The outlook on the long-term rating is negative. We could
lower the long-term rating to 'AA' within the next two years if we see that
less reduction in spending than agreed to, higher interest rates, or new fiscal
pressures during the period result in a higher general government debt
trajectory than we currently assume in our base case.
TORONTO (Standard &
Poor's) Aug. 5, 2011--Standard & Poor's Ratings Services said today that it
lowered its long-term sovereign credit rating on the United States of America
to 'AA+' from 'AAA'. Standard & Poor's also said that the outlook on the
long-term rating is negative. At the same time, Standard & Poor's affirmed
its 'A-1+' short-term rating on the U.S. In addition, Standard & Poor's
removed both ratings from CreditWatch, where they were placed on July 14, 2011,
with negative implications.
The transfer and
convertibility (T&C) assessment of the U.S.--our assessment of the
likelihood of official interference in the ability of U.S.-based public- and
private-sector issuers to secure foreign exchange for
debt service--remains
'AAA'.
We lowered our long-term
rating on the U.S. because we believe that the prolonged controversy over
raising the statutory debt ceiling and the related fiscal policy debate
indicate that further near-term progress containing the growth in public
spending, especially on entitlements, or on reaching an agreement on raising
revenues is less likely than we previously assumed and will remain a
contentious and fitful process. We also believe that the fiscal consolidation
plan that Congress and the Administration agreed to this week falls short of
the amount that we believe is necessary to stabilize the general government
debt burden by the middle of the decade.
Our lowering of the
rating was prompted by our view on the rising public debt burden and our
perception of greater policymaking uncertainty, consistent with our criteria
(see "Sovereign
Government Rating Methodology and Assumptions ," June 30, 2011,
especially Paragraphs 36-41). Nevertheless, we view the U.S. federal
government's other economic, external, and monetary credit attributes, which
form the basis for the sovereign rating, as broadly unchanged.
We have taken the ratings
off CreditWatch because the Aug. 2 passage of the Budget Control Act Amendment
of 2011 has removed any perceived immediate threat of payment default posed by
delays to raising the government's debt ceiling. In addition, we believe that
the act provides sufficient clarity to allow us to evaluate the likely course
of U.S. fiscal policy for the next few years.
The
political brinksmanship of recent months highlights what we see as America's
governance and policymaking becoming less stable, less effective, and less
predictable than what we previously believed. The statutory debt ceiling and
the threat of default have become political bargaining chips in the debate over
fiscal policy. Despite this year's wide-ranging debate, in our view, the
differences between political parties have proven to be extraordinarily
difficult to bridge, and, as we see it, the resulting agreement fell well short
of the comprehensive fiscal consolidation program that some proponents had
envisaged until quite recently. Republicans and Democrats have only been able
to agree to relatively modest savings on discretionary spending while
delegating to the Select Committee decisions on more comprehensive measures. It
appears that for now, new revenues have dropped down on the menu of policy
options. In addition, the plan envisions only minor policy changes on Medicare
and little change in other entitlements,
the containment of which
we and most other independent observers regard as key to long-term fiscal
sustainability.
Our opinion is that
elected officials remain wary of tackling the structural issues required to
effectively address the rising U.S. public debt burden in a manner consistent
with a 'AAA' rating and with 'AAA' rated sovereign peers (see Sovereign Government Rating
Methodology and Assumptions," June 30, 2011,
especially Paragraphs 36-41). In our view, the difficulty in framing a
consensus on fiscal policy weakens the government's ability to manage public
finances and diverts attention from the debate over how to achieve more
balanced and dynamic economic growth in an era of fiscal stringency and
private-sector deleveraging (ibid). A new political consensus might (or might
not) emerge after the 2012 elections, but we believe that by then, the
government debt burden will likely be higher, the needed medium-term fiscal
adjustment potentially greater, and the inflection point on the U.S.
population's demographics and other age-related spending drivers closer at hand
(see "Global Aging 2011: In The
U.S., Going Gray Will Likely Cost Even More Green, Now,"
June 21, 2011).
Standard & Poor's
takes no position on the mix of spending and revenue measures that Congress and
the Administration might conclude is appropriate for putting the U.S.'s
finances on a sustainable footing.
The act calls for as much
as $2.4 trillion of reductions in expenditure growth over the 10 years through
2021. These cuts will be implemented in two steps: the $917 billion agreed to
initially, followed by an additional $1.5 trillion that the newly formed
Congressional Joint Select Committee on Deficit Reduction is supposed to
recommend by November 2011. The act contains no measures to raise taxes or
otherwise enhance revenues, though the committee could recommend them.
The act further provides
that if Congress does not enact the committee's recommendations, cuts of $1.2
trillion will be implemented over the same time period. The reductions would
mainly affect outlays for civilian discretionary spending, defense, and
Medicare. We understand that this fall-back mechanism is designed to encourage
Congress to embrace a more balanced mix of expenditure savings, as the
committee might recommend.
We note that in a letter
to Congress on Aug. 1, 2011, the Congressional Budget Office (CBO) estimated
total budgetary savings under the act to be at least $2.1 trillion over the
next 10 years relative to its baseline assumptions. In updating our own fiscal
projections, with certain modifications outlined below, we have relied on the
CBO's latest "Alternate Fiscal Scenario" of June 2011, updated to
include the CBO assumptions contained in its Aug. 1 letter to Congress. In
general, the CBO's "Alternate Fiscal Scenario" assumes a continuation
of recent Congressional action overriding existing law.
We view the act's
measures as a step toward fiscal consolidation. However, this is within the
framework of a legislative mechanism that leaves open the details of what is
finally agreed to until the end of 2011, and Congress and the Administration
could modify any agreement in the future. Even assuming that at least $2.1
trillion of the spending reductions the act envisages are implemented, we
maintain our view that the U.S. net general government debt burden (all levels
of government combined, excluding liquid financial assets) will likely continue
to grow. Under our revised base case fiscal scenario--which we consider to be
consistent with a 'AA+' long-term rating and a negative outlook--we now project
that net general government debt would rise from an estimated 74% of GDP by the
end of 2011 to 79% in 2015 and 85% by 2021. Even the projected 2015 ratio of
sovereign indebtedness is high in relation to those of peer credits and, as
noted, would continue to rise under the act's revised policy settings.
Compared with previous
projections, our revised base case scenario now assumes that the 2001 and 2003
tax cuts, due to expire by the end of 2012, remain in place. We have changed
our assumption on this because the majority of Republicans in Congress continue
to resist any measure that would raise revenues, a position we believe Congress
reinforced by passing the act. Key macroeconomic assumptions in the base case scenario
include trend real GDP growth of 3% and consumer price inflation near 2%
annually over the decade.
Our revised upside
scenario--which, other things being equal, we view as consistent with the
outlook on the 'AA+' long-term rating being revised to stable--retains these
same macroeconomic assumptions. In addition, it incorporates $950 billion of
new revenues on the assumption that the 2001 and 2003 tax cuts for high earners
lapse from 2013 onwards, as the Administration is advocating. In this scenario,
we project that the net general government debt would rise from an estimated
74% of GDP by the end of 2011 to 77% in 2015 and to 78% by 2021.
Our revised downside
scenario--which, other things being equal, we view as being consistent with a
possible further downgrade to a 'AA' long-term rating--features less-favorable
macroeconomic assumptions, as outlined below and also assumes that the second
round of spending cuts (at least $1.2 trillion) that the act calls for does not
occur. This scenario also assumes somewhat higher nominal interest rates for
U.S. Treasuries. We still believe that the role of the U.S. dollar as the key
reserve currency confers a government funding advantage, one that could change
only slowly over time, and that Fed policy might lean toward continued loose
monetary policy at a time of fiscal tightening. Nonetheless, it is possible
that interest rates could rise if investors re-price relative risks. As a
result, our alternate scenario factors in a 50 basis point (bp)-75 bp rise in 10-year
bond yields relative to the base and upside cases from 2013 onwards. In this
scenario, we project the net public debt burden would rise from 74% of GDP in
2011 to 90% in 2015 and to 101% by 2021.
Our revised scenarios
also take into account the significant negative revisions to historical GDP
data that the Bureau of Economic Analysis announced on July 29. From our
perspective, the effect of these revisions underscores two related points when
evaluating the likely debt trajectory of the U.S. government. First, the
revisions show that the recent recession was deeper than previously assumed, so
the GDP this year is lower than previously thought in both nominal and real
terms. Consequently, the debt burden is slightly higher. Second, the revised
data highlight the sub-par path of the current economic recovery when compared
with rebounds following previous post-war recessions. We believe the sluggish
pace of the current economic recovery could be consistent with the experiences
of countries that have had financial crises in which the slow process of debt
deleveraging in the private sector leads to a persistent drag on demand. As a
result, our downside case scenario assumes relatively modest real trend GDP
growth of 2.5% and inflation of near 1.5% annually going forward.
When comparing the U.S.
to sovereigns with 'AAA' long-term ratings that we view as relevant
peers--Canada, France, Germany, and the U.K.--we also observe, based on our
base case scenarios for each, that the trajectory of the U.S.'s net public debt
is diverging from the others. Including the U.S., we estimate that these five
sovereigns will have net general government debt to GDP ratios this year
ranging from 34% (Canada) to 80% (the U.K.), with the U.S. debt burden at 74%.
By 2015, we project that their net public debt to GDP ratios will range between
30% (lowest, Canada) and 83% (highest, France), with the U.S. debt burden at
79%. However, in contrast with the U.S., we project that the net public debt
burdens of these other sovereigns will begin to decline, either before or by
2015.
Standard & Poor's
transfer T&C assessment of the U.S. remains 'AAA'. Our T&C assessment
reflects our view of the likelihood of the sovereign restricting other public
and private issuers' access to foreign exchange needed to meet debt service.
Although in our view the credit standing of the U.S. government has
deteriorated modestly, we see little indication that official interference of
this kind is entering onto the policy agenda of either Congress or the
Administration. Consequently, we continue to view this risk as being highly
remote.
The outlook on the
long-term rating is negative. As our downside alternate fiscal scenario
illustrates, a higher public debt trajectory than we currently assume could
lead us to lower the long-term rating again. On the other hand, as our upside
scenario highlights, if the recommendations of the Congressional Joint Select
Committee on Deficit Reduction--independently or coupled with other
initiatives, such as the lapsing of the 2001 and 2003 tax cuts for high
earners--lead to fiscal consolidation measures beyond the minimum mandated, and
we believe they are likely to slow the deterioration of the government's debt
dynamics, the long-term rating could stabilize at 'AA+'.
On Monday, we will
issue separate releases concerning affected ratings in the funds,
government-related entities, financial institutions, insurance, public finance,
and structured finance sectors.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.52.17 |
|
UK Pound |
1 |
Rs.80.64 |
|
Euro |
1 |
Rs.69.43 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
---- |
NB |
New Business |
---- |
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a
composite of weighted scores obtained from each of the major sections of this
report. The assessed factors and their relative weights (as indicated through
%) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.